Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HLX01 + CHOP
- Development stage
- Unknown
- Lead developer
- Henlius
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
HLX01 + CHOP is a combination therapy consisting of HLX01, a biosimilar of rituximab, and the CHOP chemotherapy regimen (cyclophosphamide, doxorubicin, vincristine, and prednisone). HLX01 is a chimeric monoclonal antibody against CD20, developed by Henlius as a biosimilar to rituximab (originator: MabThera). The mechanism of HLX01 is direct targeting of CD20 on B lymphocytes, leading to cell lysis via complement-dependent cytotoxicity, antibody-dependent cellular cytotoxicity, and apoptosis. CHOP includes three cytotoxic chemotherapy agents and prednisone, a corticosteroid. The combination is indicated for the treatment of adult patients with previously untreated, CD20-positive diffuse large B-cell lymphoma (DLBCL)[1][2][5].
- Brand names
- Hanlikang
- Other names
- HLX01-CHOPHLX-01-CHOPHLX 01-CHOPH-CHOP
02
Targets
Beyond the preview
Go deeper on HLX01 + CHOP.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HLX01 + CHOP.